SCHEMBL3015477

SCHEMBL3015477

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
HSD17B10 Q99714 2/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
POLB P06746 3/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 2/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
IDO1 P14902 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009159 0.93 MAPT (0.47) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3012512 0.93 USP2 (0.51) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3006060 0.92 MAPT (0.49) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3014474 0.91 POLB (0.49) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3016786 0.90 MAPT (0.46) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3017953 0.90 VCAM1 (0.46) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3003853 0.90 MAPT (0.48) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3006909 0.89 HSD17B10 (0.47) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3012688 0.89 USP2 (0.51) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3018783 0.89 MAPT (0.61) MAPTHSD17B10USP2RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.